Akorn, Inc. (NASDAQ:AKRX) saw unusually large options trading on Thursday. Traders purchased 17,251 call options on the stock. This represents an increase of 1,245% compared to the typical volume of 1,283 call options.
Akorn stock opened at $5.59 on Friday. Akorn has a 1 year low of $4.82 and a 1 year high of $33.63. The company has a current ratio of 3.47, a quick ratio of 2.46 and a debt-to-equity ratio of 1.26.
Akorn (NASDAQ:AKRX) last issued its quarterly earnings data on Tuesday, November 6th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by ($0.17). Akorn had a negative net margin of 34.69% and a negative return on equity of 14.97%. The business had revenue of $165.63 million during the quarter, compared to analyst estimates of $185.36 million. As a group, analysts expect that Akorn will post -0.13 EPS for the current year.
Several institutional investors and hedge funds have recently modified their holdings of AKRX. Riverhead Capital Management LLC acquired a new position in shares of Akorn in the 2nd quarter valued at approximately $100,000. Tower Research Capital LLC TRC grew its position in shares of Akorn by 672.9% in the 3rd quarter. Tower Research Capital LLC TRC now owns 10,280 shares of the company’s stock valued at $134,000 after purchasing an additional 8,950 shares during the period. Baird Financial Group Inc. acquired a new position in shares of Akorn in the 3rd quarter valued at approximately $135,000. Brown Advisory Inc. acquired a new position in shares of Akorn in the 3rd quarter valued at approximately $139,000. Finally, Meadow Creek Investment Management LLC acquired a new position in shares of Akorn in the 2nd quarter valued at approximately $157,000. Institutional investors and hedge funds own 65.00% of the company’s stock.
Akorn, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health.
Further Reading: Do You Need a Fiduciary?
Receive News & Ratings for Akorn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn and related companies with MarketBeat.com's FREE daily email newsletter.